Citryll Establishes Scientific Advisory Board for Advancements

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

Board comprises world-renowned experts in biology, immunology and pathology

Citryll, a biotech company focused on innovative treatments for immune-mediated inflammatory diseases, has announced the establishment of its Scientific Advisory Board (SAB). This Board will offer crucial strategic guidance and scientific advice as Citryll advances the development of its first-in-class monoclonal antibody, CIT-013, aimed at addressing Neutrophil Extracellular Traps (NETs).

Expertise at the Core of the Advisory Board

The formation of this Board comes with the gathering of internationally recognized experts specializing in various aspects of NET biology, pre-clinical development, and immunology. Among the founding members are Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood, and Professor Paul Kubes, each renowned for their significant contributions to medical research and drug development.

Welcoming Notable Members

"We are delighted to have such a prestigious group of experts join our Scientific Advisory Board," stated Eric Meldrum, Chief Scientific Officer of Citryll. Their extensive knowledge will be paramount in advancing CIT-013 through its clinical trials focusing on rheumatoid arthritis and hidradenitis suppurativa. With their collaboration, we expect to unlock a wealth of therapeutic potentials targeting extracellular traps in various inflammatory diseases, marking a significant milestone in expanding our advisory network as we pave the way for a Clinical Advisory Board aimed at enhancing our clinical trajectory.

Introducing the Scientific Advisory Board Members

Dr. Tim Hammond, PhD

Bringing over 35 years of expertise in pharmaceutical drug discovery, Dr. Hammond currently serves as Head of Safety across multiple organizations. His past tenure as Vice President of Safety Assessment for AstraZeneca in the UK highlights his remarkable capabilities. An esteemed independent consultant since 2012, he is lauded as a past President of the British Toxicology Society and a Fellow of the Royal College of Pathologists.

Professor John Hamilton, PhD

Prof. Hamilton is globally recognized for his influential research in macrophage biology and inflammation, with a remarkable focus on inflammatory diseases like rheumatoid arthritis. His accolades include significant awards from the Australian Rheumatology Association and the American College of Rheumatology.

Dr. Christian Lood, PhD

Dr. Lood is a leading figure in research on neutrophil function and NET formation, pivotal in understanding autoimmune diseases including systemic lupus erythematosus. He is currently an Associate Professor in the Division of Rheumatology at the University of Washington, dedicating his research to the interplay of neutrophils in various inflammatory conditions.

Professor Paul Kubes, PhD

Known for his groundbreaking work on leukocyte recruitment, Prof. Kubes is a professor at Queen’s University and holds a Canada Excellence Research Chair. His previous role as the Founding Director of the Snyder Institute for Chronic Disease at the University of Calgary underscores his influence in the field of inflammatory diseases.

About Citryll's Mission and Vision

Citryll stands at the forefront of developing transformative treatments targeting inflammatory diseases by focusing on the often-overlooked Neutrophil Extracellular Traps (NETs). This novel approach aims to create potential breakthrough therapies for a range of immune-mediated conditions.

The company is dedicated to advancing its lead product, CIT-013. This unique monoclonal antibody operates through a distinct dual mechanism by enhancing the clearance of existing NETs while inhibiting the formation of new ones.

By effectively targeting this essential driver of inflammation, CIT-013 aspires to provide an innovative and comprehensive treatment for conditions like rheumatoid arthritis and hidradenitis suppurativa, where existing therapies have often not achieved desirable disease management results.

Contact Citryll for More Information

Citryll
Sjoerd van Gorp, COO
Email: info@citryll.com

Citryll Media Contacts
ICR Healthcare
Amber Fennell, Stephanie Cuthbert, Lucy Featherstone
Email: citryll@icrinc.com

Frequently Asked Questions

What is the purpose of Citryll's Scientific Advisory Board?

The Scientific Advisory Board provides strategic guidance and scientific insights to aid in the development of Citryll's therapies, particularly CIT-013.

Who are the members of the Scientific Advisory Board?

The board includes experts such as Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood, and Professor Paul Kubes.

What is CIT-013?

CIT-013 is Citryll's first-in-class monoclonal antibody that targets Neutrophil Extracellular Traps to treat inflammatory diseases.

How does CIT-013 work?

CIT-013 enhances the removal of existing NETs and prevents the formation of new ones, aiming to reduce inflammation in patients.

Where can I find more information about Citryll?

You can reach out to Citryll via email at info@citryll.com for detailed inquiries and information.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.